4/18
12:50 pm
iccm
IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA [Yahoo! Finance]
Low
Report
IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA [Yahoo! Finance]
4/16
11:15 am
iccm
IceCure Medical Ltd (NASDAQ: ICCM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Medium
Report
IceCure Medical Ltd (NASDAQ: ICCM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
4/15
08:50 am
iccm
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer [Yahoo! Fina
Medium
Report
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer [Yahoo! Fina
4/15
08:35 am
iccm
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer
Medium
Report
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer
4/4
09:49 am
iccm
IceCure Medical Ltd (NASDAQ:ICCM) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
IceCure Medical Ltd (NASDAQ:ICCM) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
4/4
08:04 am
iccm
IceCure Medical Ltd (NASDAQ: ICCM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Medium
Report
IceCure Medical Ltd (NASDAQ: ICCM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
4/3
08:42 am
iccm
IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance
Medium
Report
IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance
4/3
08:30 am
iccm
IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance
Medium
Report
IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance
4/2
08:48 am
iccm
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes [Yahoo! Finance]
Low
Report
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes [Yahoo! Finance]
4/2
08:30 am
iccm
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes
Medium
Report
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes
3/27
08:49 am
iccm
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 [Yahoo! Finance]
Low
Report
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 [Yahoo! Finance]
3/27
08:30 am
iccm
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024
Neutral
Report
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024
3/20
12:31 pm
iccm
IceCure Medical Ltd (NASDAQ: ICCM) had its price target raised by analysts at Alliance Global Partners from $1.90 to $2.90. They now have a "buy" rating on the stock.
Low
Report
IceCure Medical Ltd (NASDAQ: ICCM) had its price target raised by analysts at Alliance Global Partners from $1.90 to $2.90. They now have a "buy" rating on the stock.
3/20
08:08 am
iccm
IceCure Medical Ltd (NASDAQ: ICCM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Medium
Report
IceCure Medical Ltd (NASDAQ: ICCM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
3/19
10:37 am
iccm
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy [Yahoo! Finance]
Low
Report
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy [Yahoo! Finance]
3/19
08:30 am
iccm
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy
Medium
Report
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy
3/15
07:00 am
iccm
5 Core Lessons For Women In Leadership [Forbes]
Low
Report
5 Core Lessons For Women In Leadership [Forbes]
3/12
08:52 am
iccm
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes [Yahoo! Finance]
Low
Report
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes [Yahoo! Finance]
3/12
08:30 am
iccm
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes
Low
Report
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes
3/7
08:41 am
iccm
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference [Yahoo! Finance]
Neutral
Report
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference [Yahoo! Finance]
3/7
08:30 am
iccm
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference
Neutral
Report
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference
3/5
08:15 am
iccm
IceCure Medical Ltd (NASDAQ: ICCM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Low
Report
IceCure Medical Ltd (NASDAQ: ICCM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
3/4
08:42 am
iccm
IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024 [Yahoo! Finance]
Medium
Report
IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024 [Yahoo! Finance]
3/4
08:30 am
iccm
IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024
Medium
Report
IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024
2/27
08:17 am
iccm
Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop [Yahoo! Finance]
Medium
Report
Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop [Yahoo! Finance]